G1H Overzicht aandelen A commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Leg je gedachten, links en bedrijfsverhaal vast
G1 Therapeutics, Inc. Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor G1 Therapeutics Historische aandelenkoersen Huidige aandelenkoers US$6.35 52 Week Hoogtepunt US$6.45 52 Week Laag US$1.04 Bèta 1.68 1 maand verandering -0.079% 3 maanden verandering 173.49% 1 Jaar Verandering 407.60% 3 jaar verandering -50.00% 5 jaar verandering -78.18% Verandering sinds IPO -55.32%
Recent nieuws en updates G1 Therapeutics, Inc.(NasdaqGS:GTHX) dropped from NASDAQ Composite Index
New minor risk - Shareholder dilution Aug 23
Second quarter 2024 earnings released: US$0.10 loss per share (vs US$0.17 profit in 2Q 2023) Aug 09 Pharmacosmos Therapeutics Inc. entered into a definitive merger agreement to acquire G1 Therapeutics, Inc. (NasdaqGS:GTHX) for approximately $390 million.
G1 Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 26 G1 Therapeutics, Inc. Provides Update on Phase 3 Presents 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer Meer updates bekijken G1 Therapeutics, Inc.(NasdaqGS:GTHX) dropped from NASDAQ Composite Index
New minor risk - Shareholder dilution Aug 23
Second quarter 2024 earnings released: US$0.10 loss per share (vs US$0.17 profit in 2Q 2023) Aug 09 Pharmacosmos Therapeutics Inc. entered into a definitive merger agreement to acquire G1 Therapeutics, Inc. (NasdaqGS:GTHX) for approximately $390 million.
G1 Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 26 G1 Therapeutics, Inc. Provides Update on Phase 3 Presents 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting May 24
CEO, President & Director recently sold €165k worth of stock May 17
Forecast to breakeven in 2026 May 10
First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2023) May 02
G1 Therapeutics, Inc., Annual General Meeting, Jun 13, 2024 Apr 28
G1 Therapeutics, Inc. to Report Q1, 2024 Results on May 01, 2024 Apr 19
Forecast breakeven date pushed back to 2026 Mar 07
Full year 2023 earnings released: US$0.93 loss per share (vs US$3.38 loss in FY 2022) Mar 01
G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024 Mar 01
G1 Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 16
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee Feb 13
Forecast to breakeven in 2025 Jan 08
G1 Therapeutics, Inc. Announces Updates, Including Encouraging Preliminary Overall Survival Data from the Ongoing Phase 2 Trial of Trilaciclib in Combination with the ADC Sacituzumab Govitecan in Patients with TNBC Jan 08
Third quarter 2023 earnings released: US$0.35 loss per share (vs US$0.59 loss in 3Q 2022) Nov 03
G1 Therapeutics, Inc. Lowers Net Revenue Guidance for the Full Year 2023 Nov 03
G1 Therapeutics, Inc. Lowers Net Revenue Guidance for the Full Year 2023 Nov 02 G1 Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023
New major risk - Share price stability Oct 16
G1 Therapeutics, Inc. Announces Resignation of Mark A. Velleca from the Board of Directors, Effective as of September 30, 2023 Sep 22
New minor risk - Market cap size Aug 15
New minor risk - Profitability Aug 10
No longer forecast to breakeven Aug 10
Second quarter 2023 earnings released: EPS: US$0.17 (vs US$0.92 loss in 2Q 2022) Aug 03 G1 Therapeutics, Inc. Provides Financial Guidance for the Full Year 2023 Aug 03
G1 Therapeutics, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 28
G1 Therapeutics Announces Appointment of Monica Thomas as Chief Compliance Officer May 24
Forecast to breakeven in 2025 May 21
Forecast to breakeven in 2025 May 12
G1 Therapeutics, Inc. Presents New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate May 11
First quarter 2023 earnings released: US$0.53 loss per share (vs US$1.15 loss in 1Q 2022) May 05
G1 Therapeutics, Inc. Reiterates Earnings Guidance for the Full Year 2023 May 04
Full year 2022 earnings released: US$3.38 loss per share (vs US$3.54 loss in FY 2021) Mar 03
G1 Therapeutics, Inc. Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with Folfoxiri + Bevacizumab for Metastatic Colorectal Cancer (CRC) (Preserve 1) Feb 15
CEO, President & Director recently sold €206k worth of stock Jan 10
G1 Therapeutics, Inc. Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib Jan 10
G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (Pfs) Data Expected in Mid-2023 Jan 05
G1 Therapeutics, Inc. Announces Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Dec 09 G1 Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $50.05 million. Nov 18
Third quarter 2022 earnings released: US$0.59 loss per share (vs US$1.00 loss in 3Q 2021) Nov 03
G1 Therapeutics, Inc. Announces Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (Adc) Nov 03
G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer Oct 27
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (Tnbc) Oct 11
Second quarter 2022 earnings released: US$0.92 loss per share (vs US$0.94 loss in 2Q 2021) Aug 04
G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors Jul 26
G1 Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 21
G1 Therapeutics, Inc. Announces Approval of COSELA by China National Medical Products Administration Jul 14 G1 Therapeutics, Inc. Announces Resignation of Willie A. Deese from the Board
G1 Therapeutics, Inc. Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer Jun 14
G1 Therapeutics, Inc. Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer Patients Prior to Chemotherapy Jun 03
G1 Therapeutics, Inc. Announces Results of A Retrospective Apr 01
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
G1 Therapeutics, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 10
G1 Therapeutics, Inc. Initiates Phase 2 Trial to Support Antitumor Mechanism of Action of Trilaciclib in Tumor Microenvironment Dec 02
G1 Therapeutics, Inc. Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with Antibody-Drug Conjugate, Trodelvy® (Sacituzumab Govitecan-Hziy) in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Nov 30
Third quarter 2021 earnings released: US$1.00 loss per share (vs US$0.31 loss in 3Q 2020) Nov 04
G1 Therapeutics Grants New Technology Add-On Payment (NTAP) for COSELA™ (Trilaciclib) by Centers for Medicare & Medicaid Services (CMS) Aug 05
G1 Therapeutics, Inc. Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer Jul 20
G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA in Bladder Cancer Jun 15 G1 Therapeutics Presents Phase 1 Data At ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant
G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA(trilaciclib) in Non-Small Cell Lung Cancer May 11
G1 Therapeutics, Inc. Announces Initiation of Phase 3 Registrational Study of COSELA (trilaciclib) in Triple-Negative Breast Cancer Apr 29
G1 Therapeutics, Inc. Announces Publication of Pooled Results from Pivotal Clinical Program of Cosela™ (Trilaciclib) in Clinical Lung Cancer Apr 27
Independent Director has left the company Apr 25
G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™, the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Mar 04
Revenue beats expectations Feb 26
G1 Therapeutics, Inc. has completed a Follow-on Equity Offering. Feb 26
G1 Therapeutics, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 18
FDA Approves G1 Therapeutics’ Cosela™ (Trilaciclib): the First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Feb 13
New 90-day high: €24.19 Feb 10
Simcere Pharmaceutical Group Limited and G1 Therapeutics, Inc. Obtains Clinical Trial Approval for Trilaciclib for Injection Issued by the Center for Drug Evaluation of National Medical Products Administration of PRC Jan 22
New 90-day high: €17.09 Jan 19
G1 Therapeutics Presents Final Phase 2 Clinical Data on Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival At 2020 San Antonio Breast Cancer Symposium Dec 12
New 90-day high: €14.80 Dec 01
G1 Therapeutics, Inc. to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium Nov 19
Insider recently bought €87k worth of stock Nov 14
New 90-day low: €9.71 Oct 29 G1 Therapeutics, Inc. Announces Executive Changes, Effective January 1, 2021
New 90-day low: €11.90 Sep 23
G1 Therapeutics, Inc. to Report Q1, 2020 Results on May 06, 2020 Sep 22 Rendement voor aandeelhouders G1H DE Biotechs DE Markt 7D 0.2% 1.2% 2.3% 1Y 407.6% -5.6% 16.7%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: G1H overtrof de German Biotechs industrie, die het afgelopen jaar een rendement -5.6 % opleverde.
Rendement versus markt: G1H overtrof de German markt, die het afgelopen jaar een rendement opleverde van 16.7 %.
Prijsvolatiliteit Is G1H's price volatile compared to industry and market? G1H volatility G1H Average Weekly Movement 24.4% Biotechs Industry Average Movement 5.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
Stabiele aandelenkoers: De aandelenkoers van G1H is de afgelopen 3 maanden volatiel geweest in vergelijking met de German markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 24% ) van G1H is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.
Over het bedrijf Meer tonen G1 Therapeutics, Inc. Samenvatting Hoe verhouden de winst en inkomsten van G1 Therapeutics zich tot de beurswaarde? G1H fundamentele statistieken Marktkapitalisatie €339.71m Inkomsten(TTM ) -€40.22m Inkomsten(TTM ) €52.28m
6.5x P/S-verhouding
-8.4x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) G1H resultatenrekening (TTM ) Inkomsten US$58.20m Kosten van inkomsten US$6.14m Brutowinst US$52.05m Overige uitgaven US$96.82m Inkomsten -US$44.77m
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -0.85 Brutomarge 89.44% Nettowinstmarge -76.93% Schuld/Eigen Vermogen Verhouding 180.2%
Hoe presteerde G1H op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2024/09/18 20:12 Aandelenkoers aan het einde van de dag 2024/09/18 00:00 Inkomsten 2024/06/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie .
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github .
Bronnen van analisten G1 Therapeutics, Inc. wordt gevolgd door 8 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Harshita Polishetty B. Riley Securities, Inc. Dane Leone BTIG Charles Butler D. Boral Capital LLC.
Toon 5 meer analisten 
